Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E76.16 EPS (ttm)2.67 Insider Own2.30% Shs Outstand332.63M Perf Week2.31%
Market Cap67.64B Forward P/E16.71 EPS next Y12.17 Insider Trans6.44% Shs Float325.86M Perf Month25.91%
Income913.50M PEG2.53 EPS next Q2.31 Inst Own66.80% Short Float1.53% Perf Quarter40.50%
Sales8.26B P/S8.19 EPS this Y198.90% Inst Trans21.33% Short Ratio1.93 Perf Half Y74.01%
Book/sh15.26 P/B13.33 EPS next Y16.63% ROA3.30% Target Price52.38 Perf Year40.38%
Cash/sh2.43 P/C83.63 EPS next 5Y30.10% ROE17.70% 52W Range106.00 - 204.66 Perf YTD42.09%
Dividend- P/FCF- EPS past 5Y19.20% ROI7.70% 52W High-0.64% Beta0.93
Dividend %- Quick Ratio1.10 Sales past 5Y58.70% Gross Margin72.70% 52W Low91.84% ATR5.36
Employees17200 Current Ratio1.40 Sales Q/Q10.50% Oper. Margin29.70% RSI (14)80.74 Volatility3.04% 2.65%
OptionableYes Debt/Eq3.18 EPS Q/Q321.60% Profit Margin11.10% Rel Volume2.34 Prev Close197.48
ShortableYes LT Debt/Eq3.04 EarningsFeb 24 BMO Payout0.00% Avg Volume2.58M Price203.35
Recom3.00 SMA2017.34% SMA5027.62% SMA20051.73% Volume6,049,866 Change2.97%
Feb-25-15Reiterated CRT Capital Buy $180 → $220
Feb-24-15Reiterated UBS Buy $165 → $222
Feb-24-15Reiterated Stifel Buy $175 → $230
Feb-12-15Reiterated RBC Capital Mkts Outperform $188 → $191
Feb-09-15Initiated Barclays Overweight $200
Jan-09-15Reiterated UBS Buy $155 → $165
Feb-28-14Reiterated UBS Buy $141 → $170
Feb-28-14Reiterated RBC Capital Mkts Outperform $151 → $158
Feb-27-14Reiterated Aegis Capital Buy $160 → $180
Jan-08-14Reiterated UBS Buy $125 → $141
Jan-08-14Reiterated Ladenburg Thalmann Buy $123 → $155
Jan-08-14Reiterated FBR Capital Outperform $130 → $153
Dec-03-13Reiterated UBS Buy $115 → $125
Nov-01-13Reiterated Ladenburg Thalmann Buy $127 → $123
Oct-30-13Initiated FBR Capital Outperform $130
Oct-07-13Reiterated CRT Capital Buy $110 → $130
Aug-08-13Reiterated UBS Buy $96 → $115
Aug-07-13Reiterated Aegis Capital Buy $135 → $140
Jul-02-13Reiterated RBC Capital Mkts Outperform $76 → $100
Jun-10-13Upgrade CRT Capital Hold → Buy $100
Mar-02-15 05:05PM  JANA Partners ups position in Valeant Pharmaceuticals Market Realist
05:01PM  Updates, advisories and surprises at MarketWatch
04:18PM  Salix swings to much-wider-than-expected loss as sales plummet at MarketWatch
12:37PM  Mallinckrodt PLC (MNK), Pfizer Inc. (PFE): Healthcor Managements Top 5 Health Stocks at Insider Monkey
12:27PM  Valeant set for $9.6bn jumbo junk sale at Financial Times
12:20PM  QLT (QLTI) Reports Wider Year-over-Year Loss in Q4 - Analyst Blog Zacks
10:42AM  3 Best Performing Stocks in February - Analyst Blog Zacks
09:05AM  The SalixValeant merger: Basics of Valeant Market Realist
09:01AM  Hedge Fund Stress, Returns, & Risk Yahoo Finance Contributors
Feb-27-15 07:08PM  10-K for Valeant Pharmaceuticals International, Inc. Company Spotlight
06:45PM  IBD 50 Stocks Outperform; Several Setups Emerge at Investor's Business Daily
03:05PM  The SalixValeant merger: Basics of Salix Pharmaceuticals Market Realist
11:06AM  Rationale of the SalixValeant merger Market Realist
11:05AM  JANA eliminates position in Cameron International Market Realist
07:00AM  Compelling Financial Benefit in Valeant's Latest Buy Morningstar
Feb-26-15 05:06PM  Basics of the SalixValeant merger transaction Market Realist
05:05PM  JANA sells stake in Equinix Market Realist
01:02PM  The SalixValeant merger will follow a cash tender timeline Market Realist
11:51AM  Jazz Pharmaceuticals Tops Q4 Earnings And Tests Buy Point at Investor's Business Daily
Feb-25-15 05:18PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 10-K, Annual Report EDGAR Online
05:16PM  Pharmacyclics considers $19bn sale at Financial Times
02:31PM  Biotech Pharmacyclics Spikes On Buyout Rumors at Investor's Business Daily
11:31AM  Here's Why CRT Capital Boosted Valeant Pharmaceuticals' Price Target Benzinga
08:02AM  Top Growth Funds: Large Caps Making Inroads at Investor's Business Daily
08:00AM  PROVENGE┬« (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer PR Newswire
08:00AM  PROVENGE┬« (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer CNW Group
Feb-24-15 04:00PM  Valeant Pharmaceuticals Is Kicking Butt, Says Canaccord Genuity Benzinga
03:58PM  Lannett Joins Big-Game Hunt For Drugmaker Acquisitions at Investor's Business Daily
01:44PM  Firms Bullish On Valeant Following Earnings, Acquisition Benzinga
12:18PM  Valeant Pharmaceuticals (VRX) Stock Higher Today as Analyst Increases Price Target on Salix Deal at TheStreet
11:39AM  Jim Cramer on Valeant: This Is an Amazing Pharmaceutical Firm at TheStreet
11:05AM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Ex EDGAR Online
10:10AM  Stock Market News for February 24, 2015 - Market News Zacks
09:31AM  Valeant Pharmaceuticals (VRX) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
09:22AM  Story Stocks from Briefing.com Briefing.com
09:00AM  Pharma ETFs in Focus on Valeant-Salix Deal - ETF News And Commentary Zacks
06:00AM  Jim Cramer's Top Stock Picks: AAPL DOW VRX XEC FTK at TheStreet
Feb-23-15 08:24PM  Jim Cramer's 'Mad Money' Recap: Calm Down, There's No Nasdaq Bubble at TheStreet +14.71%
07:53PM  Valeant Pharma (VRX) Soars on Salix Buy: 3 Keys for Investors - Stocks in the News Zacks
06:51PM  With Inversion Ban, Foreign Suitors Can Outbid Homegrown Investor's Business Daily
06:25PM  Cramer: Valeant still worth buying CNBC
06:22PM  Medical Stocks Lead New Highs On Merger News at Investor's Business Daily
05:35PM  Hedge fund Paulson & Co. to reap big reward on Salix-Valeant deal at American City Business Journals
05:03PM  Nasdaq Stretches Win Streak To 9 Days at Investor's Business Daily
04:40PM  Dow, S&P slump; Nasdaq marks 9-session win streak at MarketWatch
04:23PM  Nasdaq Climbs As Apple Stock Hits New High at Investor's Business Daily
03:22PM  Stocks Slide as Energy Weighs; Tesla Pulls Nasdaq Lower at TheStreet
03:09PM  Jim Cramer Says Investors Should Buy Valeant Pharmaceuticals (VRX) After It Acquired Salix at TheStreet
02:59PM  Drugmaker Mylan Takes Part In Pharma Feeding Frenzy at Investor's Business Daily
02:41PM  JMP Securities Comments On Salix Pharmaceutical's Takeover Valuation Benzinga
02:03PM  4 Stocks on Traders' Radars: Salix Pharma, Ocwen and More at TheStreet
01:18PM  Stocks Quietly Lower; Domino's, Medivation Break Out at Investor's Business Daily
01:03PM  Valeant shares surge 13% on Salix deal at Financial Times
12:57PM  Valeant/Salix: at what cost at Financial Times
12:50PM  Salix break-up fee signals it's serious about playing ball with Valeant at American City Business Journals
12:42PM  Salix Pharmaceuticals, Ltd. -- Moody's reviews Salix's ratings for upgrade at Moody's
12:41PM  Pharma M&A: Bristol-Myers, Valeant Make Deals at Investor's Business Daily
12:39PM  Valeant Pharmaceuticals International -- Moody's affirms Valeant's ratings; outlook remains positive at Moody's
12:19PM  Energy stocks retreat after crude declines at Financial Times
11:51AM  Valeant Surges on Salix Acquisition: What Wall Street's Saying at TheStreet
11:47AM  Stocks Edge Lower, Oil Falls, But Managed-Care Firms Shine at Investor's Business Daily
11:28AM  Salix Pharmaceuticals: Will Another Buyer Push Valeant's Bid Higher? at Barrons.com
11:28AM  Jim Cramer: Dollar General's Sales Accelerate, Valeant Is Undervalued at TheStreet
11:09AM  Stocks Slide Ahead of Yellen Speech; Boeing Weighs on Dow at TheStreet
11:03AM  Valeant soars on plan to buy Salix for $10 billion at MarketWatch
10:53AM  Valeant's approach to deals CNBC
10:48AM  Valeant CEO talks Salix acquisition CNBC
10:25AM  Valeant pops on Salix deal; Ocwen, Cooper Tire among big losers at MarketWatch
10:24AM  Stocks Open Quietly in The Red; Nationstar, Valeant, Tower Rise at Investor's Business Daily
10:22AM  Valeant Pharmaceuticals (VRX) Stock Surges Today as Analyst Ups Price Target on Salix Deal at TheStreet
09:56AM  Wolf Popper LLP Investigates Claims That the Proposed Acquisition of Salix Pharmaceuticals, Ltd. May Not Be In the Best Interests of Its Investors PR Newswire
09:53AM  Cramer's Stop Trading: DG & VRX CNBC
09:50AM  Fed in Focus This Week - Ahead of Wall Street Zacks
09:38AM  Mon., Feb. 23: Watch Honda Motor Stock at MarketWatch
09:37AM  Wall Street Eyes Heightened Greece Talks at MarketWatch
09:17AM  Morning Movers: Valeant Jumps on Salix Purchase, Earnings; Boeing Drops on Goldman Cut at Barrons.com
09:07AM  Stock Futures Dip, But Not Much; Valeant, Polypore, AerCap Surge at Investor's Business Daily
08:52AM  Cramer's stocks to watch: Amazing Valeant CNBC
08:28AM  Stock Futures Are Mixed Following a Record-Breaking Rally at TheStreet
08:23AM  Billionaire John Paulson Backs Valeant's Takeover Of Salix Pharmaceuticals Amid Consolidation Bet at Forbes
08:05AM  Wall Street watches Greece, Fed; Apple in Europe; Disney tickets top $100 Yahoo Finance
08:03AM  Dish profit top estimates, Valeant pops on deal, Apple's big investment in Europe Yahoo Finance
07:20AM  February 23 Premarket Briefing: 10 Things You Should Know TheStreet
07:02AM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financ EDGAR Online
12:02AM  These ETFs Might Enjoy the Salix Takeover News ETF Trends
Feb-22-15 08:37PM  Valeant Agrees to Buy Salix Pharma for $14.5 Billion in Cash at TheStreet
07:12PM  Valeant Pharmaceuticals Will Buy Salix For $14.5 Billion at Investor's Business Daily
06:02PM  Valeant buys Raleigh's Salix for $10 billion in cash at American City Business Journals
05:06PM  Valeant agrees to buy Salix for $14.5bn at Financial Times
04:00PM  Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash PR Newswire
04:00PM  Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash CNW Group
04:00PM  Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results PR Newswire
04:00PM  Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results CNW Group
Feb-21-15 08:29PM  Valeant nears deal to buy Salix at Financial Times
08:02AM  A Look At 5 IBD 50 Stocks With Upcoming Earnings at Investor's Business Daily
Feb-20-15 04:58PM  Stocks Cap Short Week With Gains; Salix Up On Buyout Hopes at Investor's Business Daily
04:23PM  Greek Deal Lifts Nasdaq Near Dot-Com Bubble High at Investor's Business Daily
01:32PM  Market Turns Positive As Stocks Stage Reversal at Investor's Business Daily
11:54AM  Medical Stocks Rise; Valeant Said To Be Near Buy Of Salix at Investor's Business Daily
11:42AM  Novo Nordisk Pops On Successful Diabetes Drug Trial at Investor's Business Daily
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of moderate to severe acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; and Arestin, a subgingival sustained-release antibiotic. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain. In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe that is used to rebuild and repair the skin barrier; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product. Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens. Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mirovsky PavelEVP, Pres. & GM Valeant EMEAFeb 27Option Exercise0.0010,000010,000Mar 02 05:16 PM
Stolz Brian M.EVP, Administration and CHCOJan 22Option Exercise0.007,350095,934Jan 26 05:22 PM
Schiller Howard BradleyEVP, Chief Financial OfficerJan 05Option Exercise0.0045,0000318,714Jan 07 05:38 PM
Stolz Brian M.EVP, CHCO and AdministrationDec 23Option Exercise0.0015,426096,618Dec 24 10:31 AM
Farmer Ronald HaroldDirectorDec 12Buy160.4850080,24033,004Dec 16 02:59 PM
UBBEN JEFFREY WDirectorDec 10Buy139.2950,0006,964,50018,030,936Dec 11 06:59 PM
UBBEN JEFFREY WDirectorDec 09Buy140.25200,00028,050,00017,980,936Dec 11 06:59 PM
STEVENSON KATHARINE BERGHUISDirectorDec 03Buy145.731,500218,59523,098Dec 03 04:48 PM
Farmer Ronald HaroldDirectorNov 24Buy163.951,000163,95032,504Dec 01 05:25 PM
UBBEN JEFFREY WDirectorNov 24Buy142.25210,00029,872,50017,780,936Nov 26 04:11 PM
Stolz Brian M.EVP, Administration and CHCOOct 10Option Exercise0.003,675084,791Oct 14 02:51 PM
Schiller Howard BradleyEVP and CFOOct 03Option Exercise0.0022,5000285,500Oct 07 04:19 PM
Stolz Brian M.EVP, Administration and CHCOSep 30Option Exercise0.0023,030093,064Oct 02 03:52 PM
Stolz Brian M.EVP, CHCO and AdministrationAug 06Option Exercise0.0018,111079,431Aug 07 03:53 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Jun 23Option Exercise6.4510,20365,80934,202Jun 24 04:37 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Jun 23Sale121.7010,2031,241,67623,999Jun 24 04:37 PM
Mirovsky PavelPresident of Valeant EuropeJun 02Sale131.2510,0001,312,4860Jun 04 03:19 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.May 13Option Exercise6.4510,00064,50033,999May 14 04:29 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.May 13Sale130.0810,0001,300,83623,999May 14 04:29 PM
Provencio Norma AnnDirectorApr 01Sale132.185,000660,886137,495Apr 02 04:55 PM
Kornwasser LaizerEVP, Company Group ChairmanMar 21Buy134.972,481334,85953,582Mar 25 01:06 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Mar 17Option Exercise6.455,00032,25028,999Mar 19 04:33 PM
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy.Mar 17Sale141.725,000708,60023,999Mar 19 04:33 PM